secwatch.observer — SEC 8-K summary
======================================

Issuer:     Artiva Biotherapeutics, Inc. (ARTV)
CIK:        0001817241
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-125359
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artiva Q3 2024 net loss $17.5M; cash $199.6M; AlloNK data expected H1 2025
--------------------------------------------------------------------------

- Net loss of $17.5M for Q3 2024 vs net income of $11.3M a year ago as collaboration revenue ended.
- Cash, equivalents and investments $199.6M at Sep 30, 2024; expected to fund operations through end of 2026.
- Completed upsized IPO in July 2024, gross proceeds $179.0M from 14.92M shares at $12.00.
- First patient dosed in AlloNK IIT for autoimmune diseases; initial Phase 1/1b and IIT data due H1 2025.
- Appointed Dr. Alison Moore to Board of Directors, bringing allogeneic cell therapy manufacturing expertise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817241/000095017024125359/0000950170-24-125359-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817241/000095017024125359/artv-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125359

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer